HBOT for Tinnitus | NorCal Hyperbarics Concord, CA

Tinnitus is the perception of sound — typically ringing, buzzing, hissing, clicking, or roaring — in the absence of an external source. It affects an estimated 50 million Americans to some degree, with approximately 20 million experiencing burdensome chronic tinnitus and 2 million experiencing extreme, debilitating symptoms. Tinnitus is among the most common service-connected disabilities in military veterans, often associated with noise exposure and blast injury.

Tinnitus is a symptom rather than a disease — it arises from many possible underlying causes. These include sensorineural hearing loss (the most common cause), acoustic trauma from noise exposure, Meniere's disease (endolymphatic hydrops), barotrauma from diving or pressure changes, ototoxic medications, cardiovascular disease affecting cochlear perfusion, temporomandibular joint disorders, and central auditory processing changes. The cause determines whether and which treatment is appropriate.

The critical distinction for HBOT candidacy is between peripheral tinnitus (originating in a damaged or ischemic cochlea) and central tinnitus (generated within the auditory cortex through maladaptive neural plasticity). HBOT addresses the peripheral cochlear component — specifically the cochlear ischemia and hair cell injury that produce the aberrant signals perceived as tinnitus — but has no mechanism to address centrally generated tinnitus. This distinction, which some clinics gloss over, is fundamental to setting appropriate expectations. NorCal Hyperbarics takes clinical honesty seriously on this point.

The most important thing NorCal Hyperbarics can tell you about HBOT for tinnitus is that it is not effective for all types. Tinnitus has many causes, and HBOT addresses only one of them: cochlear ischemia. Understanding whether your tinnitus falls into the treatable category requires honest clinical evaluation.

HBOT is likely to be beneficial for tinnitus that: developed acutely (not gradually over months or years); is associated with sudden sensorineural hearing loss, acoustic trauma (loud noise exposure), barotrauma (pressure injury from diving, flying, or a blast), or another identifiable cochlear vascular event; and is being treated within roughly four to eight weeks of onset, while the hair cells responsible for the aberrant signals are still injured but potentially recoverable rather than permanently dead. In these cases, the mechanism is the same as for SSNHL: the cochlea has one of the highest oxygen demands in the body and extremely limited tolerance for ischemia, and HBOT delivers oxygen concentrations sufficient to reverse cochlear hypoxia and support the recovery of injured but viable hair cells.

HBOT is unlikely to be helpful for: chronic tinnitus of long standing (more than three months without acute precipitating event); tinnitus with entirely normal hearing and no cochlear injury history; pulsatile tinnitus caused by vascular anomalies; or tinnitus that has undergone central nervous system sensitization (where the brain has reorganized around the tinnitus signal and is generating it independently of the cochlea). We will tell you clearly at consultation which category your tinnitus falls into. When HBOT is appropriate, it is typically combined with corticosteroid therapy and coordinated with your ENT physician, using protocols similar to SSNHL treatment.